Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ru-Yi-Jin-Huang Powder is a topical Traditional Chinese Medicine (TCM) herbal formulation being evaluated by Chang Gung Memorial Hospital for the treatment of radiation-induced dermatitis, particularly in head and neck cancer patients. Traditionally used to treat skin ulcers, joint swelling, and various inflammatory skin conditions, the powder is typically mixed with water or other liquids to form a paste for topical application. In the clinical setting of radiotherapy, it is investigated for its potential to mitigate skin inflammation, reduce edema, and provide pain relief. The formulation consists of a synergistic blend of traditional Chinese herbs known for their anti-inflammatory and cooling properties, though the specific herbal composition is often proprietary or standardized according to traditional pharmacopoeias. It is currently being studied in Phase 2 clinical trials (NCT04888234) to establish evidence-based efficacy for managing radiation-induced skin damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ru-Yi-Jin-Huang Powder.